drugset / Trial / NCT05911984
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.
Timeline
- Start
- 2023-06-30
- Primary completion
- 2024-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW3811 | Monoclonal antibody | — | Intravenous |